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Abstract
Background:  The treatment of Herpes-simplex-virus-encephalitis (HSVE) remains a major
unsolved problem in Neurology. Current gold standard for therapy is acyclovir, a drug that inhibits
viral replication. Despite antiviral treatment, mortality remains up to 15%, less than 20% of patients
are able to go back to work, and the majority of patients suffer from severe disability. This is a
discouraging, unsatisfactory situation for treating physicians, the disabled patients and their families,
and constitutes an enormous burden to the public health services. The information obtained from
experimental animal research and from recent retrospective clinical observations, indicates that a
substantial benefit in outcome can be expected in patients with HSVE who are treated with
adjuvant dexamethasone. But currently there is no available evidence to support the routine use
of adjuvant corticosteroid treatment in HSVE. A randomized multicenter trial is the only useful
instrument to address this question.
Design: GACHE is a multicenter, randomized, double-blind, placebo-controlled, parallel group
clinical trial of treatment with acyclovir and adjuvant dexamethasone, as compared with acyclovir
and placebo in adults with HSVE. The statistical design will be that of a 3-stage-group sequential
trial with potential sample size adaptation in the last stage.
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Conclusion: 372 patients with proven HSVE (positive HSV-DNA-PCR), aged 18 up to 85 years;
with focal neurological signs no longer than 5 days prior to admission, and who give informed
consent will be recruited from Departments of Neurology of academic medical centers in
Germany, Austria and The Netherlands. Sample size will potentially be extended after the second
interim analysis up to a maximum of 450 patients.
Trial Registration: Current Controlled Trials
ISRCTN45122933
Background
Scientific background
The treatment of herpes-simplex-virus-encephalitis
(HSVE) remains one of the major unsolved problems in
Neurology. The current gold standard in therapy is acyclo-
vir, a drug that inhibits viral replication, but despite anti-
viral treatment mortality remains up to 15%. Even after
early antiviral treatment, less than 20% of patients are
able to go back to work and the majority of patients suffer
from severe disability. Raschilas et al. [1] reported in 2002
a series of 85 patients in which 20% remained severely
disabled, 28% moderately disabled, and only 14% of
patients had a good recovery according to the Glasgow
Outcome Scale (GOS). In a series of 34 patients a mortal-
ity of 12% was described, and 40% of the surviving
patients presented an outcome ranging from moderate
disability and severe disability to vegetative state [2]. This
is a discouraging, unsatisfactory situation for treating phy-
sicians, the disabled patients and their families, and con-
stitutes an enormous burden to the public health services.
This has been an urgent topic during the last decade
despite the availability of antiviral treatment with acyclo-
vir.
Apart from direct virus-mediated tissue damage, second-
ary mechanisms have proven to play a significant role in
the pathogenesis of HSVE [3-6]. Previous work has illus-
trated that the patients who suffer from HSVE present
chronic progressive cranial magnetic resonance imaging
(MRI) abnormalities despite early antiviral treatment with
acyclovir [7]. These chronic progressive cranial MRI
abnormalities have been also observed in an experimental
mouse model of HSVE [8]. The mechanisms underlying
this virus independent structural damage are thought to
be autoimmune in nature [8]. The secondary mechanisms
may involve the expression of immunologic NO synthase,
matrix metalloproteinases and chemokines [4-6].
Viral load does not correlate with the severity of disease or
with the extent of cranial MRI abnormalities in patients
with HSVE [9]. In experimental models of HSVE the viral
load is not influenced by treatment with corticosteroids.
Despite the application of adjuvant corticosteroids, acy-
clovir effectively inhibits viral replication [10,11]. Corti-
costeroids given alone appear to have no adverse effect on
the encephalitic process during experimental HSVE [12].
In experimental animal models of HSVE the adjuvant
therapy with corticosteroids given together with the anti-
viral therapy has proven to be more effective than antiviral
therapy alone in reducing the extent of structural abnor-
malities in brain tissue observed with MRI [11].
Before acyclovir was available, steroids were used regu-
larly as the primary treatment for herpes-simplex-virus-
encephalitis. Beneficial effects with this treatment were
reported in large patient series [13,14]. Corticosteroids are
also considered to be useful for the treatment of Herpes
Encephalitis when they are administered together with the
antiviral medication [3,15]. A recent retrospective analysis
has reported a favorable outcome of patients with HSVE
receiving adjuvant therapy with corticosteroids [15].
Adjuvant corticosteroids are also used for the treatment of
patients with HSVE relapse [3].
The usefulness of an adjuvant corticosteroid treatment has
been demonstrated for infectious diseases in which an
exaggerated inflammatory response causes secondary del-
eterious effects which are independent from the infectious
agent itself, such as during bacterial meningitis [16] and
herpetical keratitis [17]. A recent prospective, multicenter,
randomized, clinical trial has demonstrated the beneficial
effect of adjuvant corticosteroids for the treatment of bac-
terial meningitis [16]. This study demonstrated that early
treatment with dexamethasone improves the outcome in
adults with acute bacterial meningitis and does not
increase the risk of gastrointestinal bleeding.
Apart from this a recent Meta-analysis has demonstrated
that short courses of high dose corticosteroids in patients
with severe sepsis and septic shock have no deleterious
effect on mortality [18]. This Meta-analysis also demon-
strated that short courses of high dose corticosteroids do
not increase the risk of superinfections, gastroduodenal
bleeding or hyperglycaemia in patients with severe sepsis
and septic shock [18].
The use of adjuvant topical corticosteroids during herpet-
ical keratitis was controversial until a prospective, control-BMC Neurology 2008, 8:40 http://www.biomedcentral.com/1471-2377/8/40
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led trial was carried out, which demonstrated that a
topical corticosteroid regimen was significantly better
than no therapy in reducing persistence or progression of
stromal inflammation and in shortening the duration of
herpes simplex stromal keratitis [17].
Kamei et al. (2005) [15] have carried out a non-ran-
domised retrospective study of 45 patients with HSVE. A
poor outcome was evident with older age, lower GCS
score at initiation of aciclovir, and no administration of
corticosteroid. Older age, lower GCS at admission and no
administration of corticosteroids were significant inde-
pendent predictors of outcome.
Rationale for the trial
The adjuvant use of corticosteroids has been recom-
mended and used by experts from neurocritical care units
in Europe and Japan for the treatment of herpes-encepha-
litis. So far however, this important question whether or
not the adjuvant treatment with corticosteroids proves to
be superior as compared to the standard antiviral treat-
ment for HSVE, has not been addressed in a randomized
trial.
The information obtained from experimental animal
research and from recent retrospective clinical observa-
tions, indicates that a substantial benefit in outcome can
be expected in patients with HSVE who are treated with
adjuvant dexamethasone. But currently there is no availa-
ble evidence to support the routine use of adjuvant corti-
costeroid treatment in HSVE. In our opinion, it is of
utmost importance to address this question in a prospec-
tive, controlled multicenter clinical trial.
Methods
Study design and setting
The study design of GACHE is that of a multicenter, rand-
omized, double-blind, placebo-controlled, parallel group
clinical trial in adult patients with herpes-simplex-virus-
encephalitis. The statistical design is that of a group
sequential design with a maximum of three stages, rejec-
tion boundaries [19] and a potential sample size adjust-
ment for the last stage [20]. Patients will be recruited from
Departments of Neurology of academic medical centers in
Germany, Austria and The Netherlands.
Ethical considerations
Full ethical approval for this study has been obtained
from all responsible Ethics Committees in Germany on
August 28th, 2006 (ref: AFmu-106/2006). The principal
investigator and/or his/her designee will obtain written
informed consent from each subject or from the subject's
legal representative or designee. Consent will be obtained
before any protocol-specific procedures will be per-
formed. All records will be kept confidential and the sub-
ject's name will not be released at any time other than the
designee's or responsible government agencies.
Study interventions
Patients will be randomly assigned to be treated either
with acyclovir and dexamethasone or with acyclovir and
placebo (Figure 1).
Treatment with Acyclovir
Acyclovir is the standard antiviral drug for the treatment
of herpes-encephalitis and is given for 14 days, as soon as
medically indicated independent from time of randomi-
zation. Acyclovir is administered intravenously at a dos-
age of 10 mg/kg body weight (BW) every eight hours with
an infusion time of 1 hour, if patients have a normal renal
function. In case of reduced creatinine clearance (<60 ml/
min) the acyclovir dosage will be adapted
Study medication (dexamethasone/placebo)
Patients will be randomly assigned to receive study medi-
cation as soon as the diagnosis of herpes-simplex-
encephalitis is confirmed with PCR. The study medication
is administered intravenously: Dexamethasone at a dos-
age of 40 mg every 24 hours for four days, or placebo that
is identical in appearance to the active drug.
Labeling, dispensing, storage and accountability
Labelling of masked study medication (dexamethasone
respectively placebo) and dispensing will be performed
centrally by the Pharmacy of the University of Heidelberg.
The study medication can be stored for three years at
room temperature. A 'drug accountability log' or a corre-
sponding document will be maintained at each trial
center and has to be up-to-date at all times.
Concomitant medication
All medications are allowed with exception of actual or
long-standing corticosteroid treatment. Gastric protection
with an antacid medication is obligatory during the
administration of the study medication.
Treatment compliance
The treatment procedures are administered in the trial
centers during the acute phase of the disease; therefore
there does not exist any problems with treatment compli-
ance. The treating physicians as well as the patient are
blinded.
Primary and secondary endpoints
Primary endpoint
Binary functional outcome 6 months (± 14 days) after
randomization (measured by the modified Rankin scale,
a seven-point-scale from 0 to 6 points). A mRS of 3 to 6
will be seen as an unfavourable outcome (= failure).BMC Neurology 2008, 8:40 http://www.biomedcentral.com/1471-2377/8/40
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Schematic diagram of study design Figure 1
Schematic diagram of study design.
Figure: Schematic diagram of study design  
Admission, baseline data, CT scan, lumbal puncture for CSF, start of treatment with acyclovir
Proof of diagnosis by CSF analysis for detection of HSV-DNA with PCR assay 
Selection of patients with respect to the inclusion and exclusion criteria 
Randomization
Day 0 of study 
Experimental group:  
Treatment with adjuvant 
dexamethasone 
Aciclovir: 10mg/kg BW  acyclovir 
(intravenously, 1 hour infusion) every 8 hours 
for 14 days 
Dosage adaptation in case of decreased 
creatinine clearance 
 Dexamethasone 40 mg intravenously every 24 
hours for 4 days. 
Control group:  
Treatment with placebo 
Aciclovir:  10mg/kg BW  acyclovir 
(intravenously, 1 hour infusion) every 8 hours 
for 14 days 
Dosage adaptation in case of decreased 
creatinine clearance 
 Placebo identical in appearance to 
dexamethasone infusion every 24 hours for 4 
days
Day 0  x Neurological examination, GCS, pre-encephalitis Barthel Index, pre-
encephalitis mRS, Neuropsychological test, seizures.
x Cranial MRI-scan as soon as possible after positive HSV in CSF, at the 
latest 48 hours after initiation of study medication 
(Dexamethasone/Placebo).
Day 7  x Physical and neurological examinations.
Discharge at the 
latest Day 30 
x Physical and neurological examinations, mRS, GOS, Barthel index, seizures.
6 months after 
randomization  
x Physical, neurological and neuropsychological examinations, mRS, GOS, 
qualitiy of life (EuroQol 5D), Barthel-Index, seizures.  
x Cranial MRI-scan. 
12 months after 
randomization  
x Physical and neurological examinations, mRS, GOS, quality of life (EuroQol 
5D), Barthel-Index, seizures. BMC Neurology 2008, 8:40 http://www.biomedcentral.com/1471-2377/8/40
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Patients dying between randomization and 6 months fol-
low-up will be evaluated with mRS = 6.
Secondary endpoints
1. Mortality at 6 months after randomization.
2. Mortality at 12 months after randomization.
3. Functional outcome (Glasgow outcome scale: GOS)
and quality of life (EuroQol 5D) 6 months (± 14 days)
after randomization.
4. Functional outcome (mRS, GOS) and quality of life
(EuroQol 5D) 12 months (± 28 days) after randomiza-
tion.
5. Neuropsychological testing 6 months (± 14 days) after
randomization.
6. MRI at 6 months (± 14 days) after randomization.
7. Seizures up to discharge (or at the latest at day 30), 6
months and 12 months after randomization.
Selection and withdrawal of subjects
Subject inclusion criteria
￿ Age: ≥ 18 to ≤ 85 years.
￿ Laboratory – proven diagnosis of herpes-simplex-virus-
encephalitis (PCR detection of HSV-DNA in the CSF)
￿ Focal neurological signs for not more than 5 days prior
to admission.
￿ Informed consent.
￿ Women of childbearing potential: negative pregnancy
testing in urine.
Every study center will keep a screening log which will
contain the data of every patient who were initially treated
with acyclovir due to suspected HSV-encephalitis during
the enrolment period but who did not enter the study.
Due to suspected diagnosis these patients could eventu-
ally be included in this trial.
Subject exclusion criteria
￿ History of hypersensitivity to corticosteroids.
￿ Systemic corticosteroid treatment within the last six
months or at present time (>20 mg p.o. or generally intra-
venous intake).
￿ Two fixed dilated pupils.
￿ Pre-event score modified Rankin Scale (mRS) more than
two or Barthel Index less than 95.
￿ Pregnancy.
￿ Breast feeding women.
￿ Recent history of active tuberculosis or systemic fungal
infection.
￿ Recent head trauma/neurosurgery/peptic ulcer disease.
￿ Life expectancy less than three years.
￿ Other serious illness that confound treatment assess-
ment.
￿ Simultaneous participation in another clinical trial.
￿ Previous participation in another clinical trial in the last
30 days.
￿ Previous participation in this clinical trial.
￿ Women of childbearing potential who are not using a
highly effective birth control method.
￿ Acute viral infections other than HSVE (herpes zoster,
poliomyelitis, chickenpox).
￿ Hepatitis B surface Antigen (HBsAg)-positive chronic
active hepatitis.
￿ Approximately eight weeks before to two weeks after
prophylactic vaccination.
￿ Lymphadenitis following Bacille Calmette Guérin
(BCG) vaccination.
Subject withdrawal criteria
Patients will be withdrawn from the trial because of the
following reasons:
￿ The patient or the legally authorized representative with-
draws his/her declaration of consent or wishes to break off
the trial.
￿ It becomes known after the patient's inclusion into the
study that a major patient selection criterion was violated
at the time of randomization.
The documentation of withdrawals will be done on a sep-
arate screening list of all patients.BMC Neurology 2008, 8:40 http://www.biomedcentral.com/1471-2377/8/40
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A patient will be withdrawn from the treatment if one of
the following events take place:
￿ When an unexpected event results in a medical treat-
ment that is not compatible with the trial protocol.
￿ The undesired effect of a concomitant medication makes
it necessary to discontinue the treatment according to the
protocol.
￿ A severe adverse event necessitates the termination of
the study treatment.
Patients withdrawn from treatment are not withdrawn
from the study, but are followed and evaluated according
to the protocol.
Trial procedures for the individual patient
An overview over all examinations and tests carried out
during the study is given in the following list:
Initial data on admission.- Baseline data: Age, sex, body
weight and height, date and time of onset of symptoms,
date and time of admission to the hospital, medical his-
tory, physical examination, GCS. CT scans on admission
prior to randomization, seizures. Start of treatment
Day 0 (at randomization): Neurological examination,
pre-encephalitis scores on mRS and Barthel-Index, GCS,
Neuropsychological test. CSF analysis and result of posi-
tive polymerase chain reaction assay. Women of child-
bearing potential: birth control method, pregnancy
testing in urine.
Day 0 or as soon as possible after positive HSV PCR, at the
latest 48 hours after initiation of study medication (Dex-
amethasone/placebo): MRI-scan.
Day 7 to 10 after randomization: Physical and neurologi-
cal examination.
At discharge, at the latest Day 30 after randomization:
Physical and neurological examination, mRS, GOS, Bar-
thel Index, seizures.
6 months after randomization: Physical and neurological
examination, neuropsychological testing, mRS, GOS, Bar-
thel-Index, cranial MRI, seizures, EuroQol-5D.
12 months after randomization: Physical and neurologi-
cal examination, mRS, GOS, Barthel-Index, seizures,
EuroQol-5D.
Randomization
Study treatment allocation (dexamethasone respectively
placebo) will be done in a ratio 1:1 by the method of min-
imization (Pocock and Simon 1975) considering two fac-
tors, study center and Glasgow coma scale (dichotomized:
≤ 8, >8). This method is preferred to a stratified block ran-
domization because of the large number of strata (at least
50) which could possibly induce pronounced imbalance
between the treatment groups. Each center will be pro-
vided with a series of study medication (dexamethasone
or placebo) in a randomly order.
The described kind of randomization has to be done cen-
trally. The preferred implementation is the web-based
software Randomizer provided by the Institute of Medical
Informatics, Statistics and Documentation of the Medical
University of Graz http://www.randomizer.at which ide-
ally will be used by all participation centers. If this proce-
dure is not not applicable for some centers, the procedure
is carried out by persons of the IMBI, who are not involved
in the data management or the statistical analysis of the
study and who are called by phone. In special cases (on
weekends), if it is impossible to receive the next allocation
number in time (within two hours), the trial center has to
use the next following code number of their preparation
series. This has to be reported synchronously to the Insti-
tute of Medical Biometry and Informatics (IMBI). The
next central allocation will minimize the possibly accrued
imbalance.
Blinding
GACHE is a double-blind clinical trial with the patient,
the treating physician, the observer and all other site per-
sonnel as well as the monitor being unaware of the treat-
ment assignment. Dexamethasone and placebo will be
provided in identically appearing vials and study kits.
Monitoring of adverse events
The independent DSMC will be responsible for reviewing
subject safety during the trial. The major function of this
committee will be to monitor the safety and efficacy of the
study and to provide recommendations regarding further
enrolment and conduct of the trial. The DSMC will peri-
odically review tabulated safety summaries and addi-
tional safety data which the DSMC may request during the
conduct of the trial. The DSMC is responsible for making
recommendations to a Steering Committee regarding
modifications or stopping of the trial based on observed
safety and results of planned interim analyses.
Statistics
Analysis sets
There will be three different analysis sets: the full analysis
set, the per protocol analysis set and the safety analysis set.
The full analysis set includes all patients who are rand-BMC Neurology 2008, 8:40 http://www.biomedcentral.com/1471-2377/8/40
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omized. The per protocol analysis set encloses all patients
who were treated and observed as outlined in the proto-
col. The safety analysis set contains all patients who were
treated at least for one day.
Analysis strategy
The primary endpoint analysis will be based on the full
analysis set and will follow the intention-to-treat princi-
ple. For patients lost to follow up the last observation car-
ried forward approach is applied. In addition sensitivity
analyses will be added to estimate worst case and best case
scenarios.
The statistical design will be based on a group sequential
trial with a maximum of three stages and rejection bound-
aries according to O'Brien/Fleming [21]. After the second
stage a sample size adjustment using the conditional rejec-
tion probabilities approach [22] and the sample size formula
for binary data [23] is planned.
The (maximal) two interim analyses are carried out when
one respectively two third of the originally planned
patients (372 randomized patients; 312 patients without
15% drop outs) have passed the 6 months follow-up. In
each of the analyses, the interim analyses and the final
analysis, the nullhypothesis of equal failure rates pcontrol
(acyclovir monotherapy group) and pexp (group of acyclo-
vir and corticosteroids) after 6 months
H0: pcontrol = pexp H1: pcontrol ≠ pexp
is tested by a (two-sided) χ2-test with one degree of free-
dom. The overall type I error rate is fixed to α = 0.05, the
overall power to 1-β = 0.8.
If there is no significant result either in the first interim
analysis or in the second interim analysis, a sample size
adjustment for the last stage is carried out after the second
stage.
In case of a significant result in any of the above described
analyses, the same null-hypothesis of equal rates will be
tested for the first secondary endpoint (mortality after 6
months), applying the same nominal significance level as
in the test about the primary endpoint. Again, if this
hypothesis can be rejected, the same null-hypothesis will
be tested for the second secondary endpoint (mortality
after 12 months), once more to the same nominal signif-
icance level. Due to the a priori ordering of the 3 hypoth-
eses, this strategy can allow confirmatory conclusions for
all tests without further increase of the overall type I error
[24].
Criteria for termination/extension of the trial
After each interim analysis the Data and Safety Monitor-
ing Committee (DSMC) will review the data and the
interim results and give recommendations to the Steering
Committee (SC) whether to CONTINUE or DISCON-
TINUE the trial on the basis of the difference in the failure
rates between the treatment groups and on the basis of the
mortality rates:
a.) Failure rates after 6 months differ significantly between
the groups:
The DSMC will recommend to STOP the study and the
study will be STOPPED by the DSMC.
b.) Failure rates after 6 months do not differ significantly
between the groups:
The DSMC will recommend to CONTINUE the study if
there is no remarkable difference in the mortality rates
between the treatment groups.
In addition, a sample size recalculation as described
below will be carried out in the second interim analysis.
The DSMC will recommend to CONTINUE the study
until the newly estimated number of patients or a maxi-
mum of 450 patients are recruited.
The final decision to CONTINUE or to STOP the trial is
made by the SC. The decision of the SC is based on the rec-
ommendation of the DSMC as well as important addi-
tional information available at the second interim
analysis like new scientific knowledge, the actual patient
enrolment and the financial situation.
Detailed statistical methods
The detailed statistical methods (statistical tests, confi-
dence intervals etc.) will be described in the statistical
analysis plan for the interim and the final analyses the
analysis plan for the final analysis. Here, especially treat-
ment by center interactions (centers adequately pooled
before unblinding) as well as treatment by GCS (Glasgow
Coma Scale) interactions will be investigated in a logistic
regression model.
Sample size
In their large retrospective multicenter study of epidemio-
logical features of herpes-simplex – encephalitis type I a
failure rate of 35% for acyclovir monotherapy was
reported [1]. The randomized clinical trial for dexametha-
sone in adults with bacterial meningitis [16] resulted in a
failure rate of 25% in the placebo group and a failure rate
of 15% in the experimental group. These results cannot be
directly transferred because on the one hand the medical
indication is different to GACHE and on the other hand inBMC Neurology 2008, 8:40 http://www.biomedcentral.com/1471-2377/8/40
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both cited studies the primary endpoint is based on the
Glasgow Outcome Scale (GOS) and the time period of
observation after randomization as well as the cut-off
point for dichotomization is defined differently.
Due to this lack of data from former research about the
distribution of the here chosen primary endpoint the
study design of GACHE is based on a group sequential
trial [19] with a maximum of three stages and an adapta-
tion of the sample size in the last stage [22].
The sample size calculation is started with the pure group
sequential design without taking into account the adapta-
tion: For the planning phase at the beginning of the study
a failure rate of pcontrol = 0.4 in the acyclovir monotherapy
group and a failure rate of pexp = 0.25 for the combination
therapy of acyclovir plus corticosteroids is assumed. For a
specified type I error rate of α = 0.05 and equally spaced
stages this treatment difference can be detected with a
power of 1-βbegin = 0.8 if a maximum of 52 patients per
group and stage are included, i.e. the maximum total sam-
ple size is 312 patients (ADDPLAN; Release 3). Assuming
a rate of loss to follow-up of 15% 62 patients per group
have to be enrolled in each stage which results in a maxi-
mum of 372 patients for the entire study.
In the second interim analysis a sample size recalculation
based on the pooled data of the first and second stage is
carried out and defines the final sample size for the entire
study. First, the conditional rejection probabilities under the
null-hypothesis H0 [22] are calculated. Using furthermore
the estimated failure rates in the control group and in the
experimental group for the variance estimation, a clini-
cally relevant difference in the rates of 0.15 (as in the
beginning) as well as a power of 90% for the last stage the
sample size for the last stage is calculated [23]. This strat-
egy, here called combined strategy of the groupsequential
design and the adaptive design yields a final sample size
of between 208 patients and (theoretically) infinity. To
avoid a possible unrealistic large sample size a maximum
limit for the total amount of patients has to be defined
due to the rareness of the disease. At the moment as max-
imum limit a sample size of 450 patients for the whole
study seems to be reasonable.
A simulation study for different failure rates in the control
group (pcontrol = 0.3; 0.4; 0.5; 0.6) and the fixed relevant
treatment difference of 0.15 shows that the power of the
described combined strategy is always slightly greater than
the power of the pure group sequential design while
maintaining the prespecified overall significance level of α
= 0.05. The simulated power for the case of pcontrol = 0.4 is
1-β = 0.82. As expected, in all simulated settings the aver-
age sample size (ASN) under the alternative H1 is also
greater in the combined strategy than in the simple group
sequential approach. However, if the assumptions upon
the failure rate in the control group at the beginning of the
study are not fulfilled the sample size adaptation after the
second stage in the combined strategy leads to a smaller
deviation from the desired power of 80% in comparison
to O'Brien/Fleming [19]. Furthermore, the described com-
bined strategy theoretically offers the possibility to change
also other design aspects. However, if taken into consider-
ation, such alterations always have to be considered with
caution and thoroughly discussed by the DMSC and the
SC. The one aspect, which can be of interest in this study,
is the change of the maximum limit of 450 patients
(which is based on practical considerations) depending
on actual experience with the recruitment rate.
Time plan for the GACHE Trial
Patient recruitment began in November 2007 and is
planned to continue until June 2013. For the trial synop-
sis see Table 1.
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Table 1: Trial synopsis
Title of the Trial German Trial of Acyclovir and Corticosteroids in Herpes-simplex-virus-Encephalitis (GACHE): a 
multicenter, multinational, randomized, double-blind, placebo-controlled German, Austrian and 
Dutch trial [ISRCTN45122933]
Indication Herpes-simplex-virus-encephalitis
Trial locations Departments of Neurology of academic medical centers in Germany, Austria and the Netherlands.
Design Multicenter, randomized, double-blind, placebo-controlled, parallel group clinical trial of treatment with acyclovir 
and adjuvant dexamethasone, as compared with acyclovir and placebo in adults with herpes-encephalitis. The 
statistical design will be that of a 3-stage-group sequential trial with potential sample size adaption in the last stage.
Objectives The purpose of this study is to assess the efficacy and safety of adjuvant dexamethasone in the treatment of adult 
patients with herpes-encephalitis.
Eligibility criteria – inclusion Proven herpes-encephalitis (positive HSV-DNA-PCR); age 18–85; focal neurological signs not longer than 5 days 
prior to admission, informed consent, women of childbearing potential: negative pregnancy testing in urine.
Eligibility criteria – exclusion History of hypersensitivity to corticosteroids, systemic corticosteroid treatment within the last 6 months or at 
present time, two fixed dilated pupils, pre-event score mRS >2 or Barthel Index<95, pregnancy, breast feeding 
women, recent history of active tuberculosis or systemic fungal infection, recent head trauma/neurosurgery/peptic 
ulcer disease, life expectancy < 3 years, other serious illness that confound treatment assessment, simultaneous 
participation in another clinical trial, previous participation in another clinical trial in the last 30 days, previous 
participation in this clinical trial, women of childbearing potential who are not using a highly effective birth control 
method, acute viral infections other than HSVE (herpes zoster, poliomyelitis, chickenpox), Hepatitis B surface 
Antigen (HBsAg)-positive chronic active hepatitis, approximately eight weeks before to two weeks after prophylactic 
vaccination, lymphadenitis following Bacille Calmette Guérin (BCG) vaccination.
Treatment Experimental Group: 10 mg/kg BW acyclovir (i.v., 1 hour infusion) every 8 hours for 14 days (Dosage adaptation in 
case of decreased creatinine clearance) + dexamethasone 40 mg intravenously every 24 hours for 4 days
Control Group: 10 mg/kg BW acyclovir (i.v., 1 hour infusion) every 8 hours for 14 days (Dosage adaptation in case 
of decreased creatinine clearance) + Placebo every 24 hours for 4 days
Endpoints Primary Endpoint: Binary functional outcome after 6 months measured by the modified Rankin scale (mRS), a seven-
point-scale 0 – 6. A mRS-score of 3 to 6 will be seen as an unfavourable outcome.
Secondary endpoints: Mortality after 6 and 12 months, functional outcome after 6 months measured by Glasgow 
outcome scale (GOS) and quality of life (EuroQol 5D), functional outcome after 12 months (mRS, GOS) and quality 
of life (EuroQol 5D), neuropsychological testing after 6 months, cranial MRI findings after 6 months, Seizures up to 
day of discharge or at the latest at day 30, and after 6 and 12 months.
Examinations/Follow-up Day 0, 7, at discharge (at the latest at day 30), 6 months and 12 months after randomization.
Sample size 372 patients, potential sample size extension after the second interim analysis up to a maximum of 450 patients
Trial duration: 9 years: 2 years and 6 months preparation, 5 years and 6 months recruitment, 1 year follow-up.
Steering committee Prof. Dr. Uta Meyding-Lamadé; Department of Neurology, Krankenhaus Nordwest, Frankfurt am Main
Prof. Dr. W. Hacke, Director, Department of Neurology, University of Heidelberg
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